unruptured cerebral aneurysm
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients who provide informed consent for the trial. 2. Patients who are no~low response to Clopidogrel
Exclusion criteria
Exclusion criteria: 1. Patinets who are treated with anticoagulation drugs (warfarin and NOAC) and /or antiplatelet drugs other than Aspirin and Clopidogrel. 2. Patients with abnormal platelet count (<50000/microL) 3. Patients with active bleeding (GI tract, etc) 4. Patients who are allergic to Prasugrel 5. Patients who are indicated for parent artery occlusion 6. Patients who are considered unsuitable for the trial by the responsible researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of clinical thromboembolic and hemorrhagic complication | — |
Secondary
| Measure | Time frame |
|---|---|
| Frequency of thromboembolic complication detected by MRI(Diffusion Weighted Image) within postoperative 5 days. Frequency of cerebral infarction and hemorrhagic complication on brain CT scan at 2~4 weeks after the endovascular surgery | — |
Countries
Japan
Contacts
Fujita Health University, Faculty of Medicine Department of Neurosurgery